从基层到三甲:脂肪性肝病纤维化患病率及无创检测适用性
该研究回顾性纳入2016至2024年五个队列,覆盖普通人群、代谢异常人群及肝病门诊转诊者,评估纤维化患病率及实验室无创检测的准确性。结果显示基层/二级医疗中疑似纤维化约7%,纤维化四项指数敏感性低,LiverPRO和LiverRisk评分可优化转诊路径。
要点
- 基层/二级医疗中疑似纤维化(LSM≥8 kPa)约7%,糖尿病或肥胖者患病率更高。
- 纤维化四项指数≥1.3在基层/二级医疗敏感性仅33%-44%,阳性预测值8.3%-12%。
- LiverPRO最敏感、LiverRisk评分最特异,可优化脂肪性肝病转诊策略。
核心结论
- 当代脂肪性肝病患者中,基层/二级医疗纤维化患病率约7%,糖尿病或肥胖者尤为突出。
- LiverPRO和LiverRisk评分可优化转诊路径。
研究设计与样本
- 回顾性纳入2016至2024年五个队列,覆盖基层至三甲医疗。
- 队列I为结肠镜筛查普通人群n=1185(基层);队列II超重n=1333、队列III糖尿病前期n=996(二级);队列IV/V肝病门诊n=2598/n=2397(三甲)。
主要发现
- 平均受控衰减参数为262至294 dB/m,41%至64%存在肝脂肪变。
- 疑似纤维化(LSM≥8 kPa)在队列I为6.4%,队列II/III为7.3%/6.8%,队列IV/V为21%/30%。
- 进展期纤维化(≥12 kPa)罕见:队列I为1.2%,队列II/III为1.4%/0.8%,队列IV/V为12%/17%。
- 纤维化四项指数≥1.3对LSM≥8 kPa的敏感性在基层/二级为33%-44%,阳性预测值8.3%-12%,AUPRC为0.09-0.15。
- LiverPRO(AUPRC 0.12-0.24)和LiverRisk评分(AUPRC 0.13-0.24)数值上更准确,LiverPRO最敏感、LiverRisk评分最特异。
关键数值与推荐
- 疑似纤维化定义为LSM≥8 kPa,进展期纤维化定义为LSM≥12 kPa。
- 纤维化四项指数≥1.3用于预测LSM≥8 kPa。
- LiverPRO和LiverRisk评分可作为一线无创检测优化转诊。
临床怎么用
- 在基层/二级医疗中,对脂肪性肝病患者应优先考虑LiverPRO或LiverRisk评分而非纤维化四项指数进行风险分层。
- 糖尿病或肥胖患者纤维化风险较高,需更积极筛查。
- 三甲医疗中LiverPRO较纤维化四项指数更敏感,可用于转诊评估。
局限性
- 回顾性研究设计可能引入选择偏倚。
- 未报告外部验证队列的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Knowing the prevalence of fibrosis, the accuracy of noninvasive tests, and their applicability in referral strategies of individuals screened or surveilled for steatotic liver disease is crucial for individual and policy decision making. METHODS: Five cohorts spanning primary to tertiary care between 2016 and 2024 were retrospectively included: individuals from the general population (colonoscopy screening, n = 1185, cohort I; primary care); at-risk individuals with metabolic dysfunction (overweight n = 1333, cohort II; prediabetes, n = 996, cohort III; secondary care); and subjects referred to hepatology clinics (n = 2598/n = 2397, cohort IV/V; tertiary care). RESULTS: Mean controlled attenuation parameter was 262 to 294 dB/m, and 41% to 64% showed hepatic steatosis. Suspected fibrosis (liver stiffness measurement [LSM] ≥8 kPa) was found in 6.4% of cohort I, 7.3%/6.8% of cohort II/III, and 21%/30% of cohort IV/V, whereas advanced fibrosis (≥12 kPa) was rare (1.2% in cohort I, 1.4%/0.8% in cohorts II/III, and 12%/17% in cohorts IV/V, respectively). The prevalence of fibrosis was especially high in subjects with obesity or diabetes, but not in overweight or prediabetes. Sensitivity of Fibrosis-4 index ≥1.3 for liver stiffness measurement ≥8 kPa was low in primary and secondary care (33%-44%) with simultaneously low positive predictive value (8.3%-12%), and overall low accuracy (area under the precision recall curve [AUPRC], 0.09-0.15). LiverPRO (AUPRC, 0.12-0.24) and LiverRisk score (AUPRC, 0.13-0.24) were numerically more accurate, with LiverPRO being the most sensitive and LiverRisk score the most specific first-line test. In tertiary care, LiverPRO was comparatively accurate, but more sensitive than Fibrosis-4 index. CONCLUSIONS: Prevalence of fibrosis in contemporary patients with steatotic liver disease was ∼7% in primary/secondary care, being especially pronounced in individuals with diabetes or obesity. LiverPRO and LiverRisk score optimize referral pathways.
引用
- Semmler G, Thöne P, Embacher J, et al. Prevalence of Fibrosis and Applicability of Lab-Based Noninvasive Tests From Primary to Tertiary Care. Clin Gastroenterol Hepatol. 2025. PMID: 40967446. doi:10.1016/j.cgh.2025.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。